Integrated Filing — IndAS



General information about company

Scrip Code 532612
NSE Symbol INDOCO
MSEI Symbol NOTLISTED
ISIN INE873D01024
Name of company INDOCO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 03-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 03-02-2026   11:05:00
End date and time of board meeting 03-02-2026   11:50:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 44,536.00 1,36,971.00
Other income 98.00 337.00
Total income 44,634.00 1,37,308.00
2 Expenses
(a) Cost of materials consumed 9,789.00 31,641.00
(b) Purchases of stock-in-trade 3,299.00 11,104.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,046.00) (2,672.00)
(d) Employee benefit expense 10,603.00 31,628.00
(e) Finance costs 2,564.00 7,632.00
(f) Depreciation, depletion and amortisation expense 3,201.00 9,396.00
(f) Other Expenses
1 RESEARCH & DEVELOPMENT EXPENSES 1,831.00 6,178.00
2 OTHER EXPENSES 16,909.00 49,882.00
Total other expenses 18,740.00 56,060.00
Total expenses 47,150.00 1,44,789.00
3 Total profit before exceptional items and tax (2,516.00) (7,481.00)
4 Exceptional items (615.00) (668.00)
5 Total profit before tax (3,131.00) (8,149.00)
6 Tax expense
7 Current tax 1.00 6.00
8 Deferred tax (187.00) (655.00)
9 Total tax expenses (186.00) (649.00)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (2,945.00) (7,500.00)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (2,945.00) (7,500.00)
17 Other comprehensive income net of taxes (126.00) 117.00
18 Total Comprehensive Income for the period (3,071.00) (7,383.00)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (2,979.00) (7,350.00)
Total profit or loss, attributable to non-controlling interests 34.00 (150.00)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent (3,105.00) (7,233.00)
Total comprehensive income for the period attributable to owners of parent non-controlling interests 34.00 (150.00)
21 Details of equity share capital
Paid-up equity share capital 1,845.00 1,845.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -3.2 -8.14
Diluted earnings (loss) per share from continuing operations -3.19 -8.13
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -3.2 -8.14
Diluted earnings (loss) per share from continuing and discontinued operations -3.19 -8.13
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1.The unaudited Consolidated Results for the quarter and Nine months ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 03rd February, 2026. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Quarter Quarter Quarter Nine months Nine months Year & Ended Ended Ended Ended Ended Ended Income from 31.12.2025 30.09.2025 31.12.2024 31.12.2025 31.12.2024 31.03.2025 Operation (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) India 29,544 30,370 28,162 87,698 82,853 1.09,039 Outside India 13,890 16,813 12,083 46,006 42,887 55,090 Total 43,434 47,183 40,245 1,33,704 1,25,740 1,64,129 5. The Consolidated Financial Results includes the Results of the following Companies ---------------------------------------------------------------------------------------------------------------------------------- Name of theCompany % of shareholding Consolidated as --------------------------------------------------------------------------------------------------------------------------------- Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech SRO 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Limited 100.00 Subsidiary FPP Holding Company , LLC 85.00 Subsidiary ================================================================================ 6.The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2025. 7. (*) Exceptional items includes : (a) Consideration received Rs. 253 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, (c) Impact of past period employee benefit liability amounting to Rs. 708 lakhs due to implementation of the New Labour Codes. 8. Effective 21 November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 708 lakhs primarily arising due to change in definition of wages for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Group has presented such incremental impact under 'Exceptional Item in the consolidated financial results for the quarter and nine months ended 31st December, 2025. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS (77.00) (230.00)
Total Amount of items that will not be reclassified to profit and loss (77.00) (230.00)
2 Income tax relating to items that will not be reclassified to profit or loss (19.00) (57.00)
3 Amount of items that will be reclassified to profit and loss
1 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS (48.00) 404.00
Total Amount of items that will be reclassified to profit and loss (48.00) 404.00
4 Income tax relating to items that will be reclassified to profit or loss 20.00 114.00
5 Total Other comprehensive income (126.00) 117.00